Abstract: The present invention relates to a polymer composition comprising (85-100 wt %) of a propylene copolymer based on the total amount of the polymer composition, wherein the comonomer in the propylene copolymer is selected from moiety derived from ethylene, an ?-olefin having (4) to (20) carbon atoms or a combination thereof, wherein the amount of the comonomer is in the range of (0.50 to 4.5) wt % based on the propylene copolymer, wherein the fraction of melted propylene copolymer in the temperature range from (116 to 151° C.) is in the range from (65 to 90) wt % based on the total weight of the propylene copolymer. The present invention also relates to expanded polypropylene (EPP) beads comprising said polymer composition. The invention further relates to the use of such EPP beads. The invention further relates to a process for preparing such EPP beads. The present invention also relates to an article made from said EPP beads. The invention further relates to the use of such article.

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Abstract: The present invention relates to a polyethylene composition comprising a) a polyethylene blend comprising from 95.5% to 99.5 wt % low density polyethylene (LDPE) and from 0.5% to 4.5 wt % high density polyethylene (HDPE), wherein the wt % (% by weight) is based the total amount of low density polyethylene and high density polyethylene in the blend, and b) a mixture of glycerol-mono-stearate and glycerol-mono-palmitate.

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.

Abstract: Methods and apparatuses for position determination and other operations. In one embodiment of the present invention, a mobile station uses wireless signals from a plurality of wireless networks (e.g., with different air interfaces and/or operated by different service providers) for position determination (e.g., for data communication, for obtaining time and/or frequency information, for range measurement, for sector or altitude estimation). In one embodiment of the present invention, mobile stations are used to harvest statistical data about wireless access points (e.g., the locations of mobile stations that have received signals from the wireless access points, such as from cellular base stations, wireless local area network access points, repeaters for positioning signals, or other wireless communication transmitters) and to derive location information (e.g., position and coverage area of the wireless access points) for the wireless networks from the collected statistical data.

Abstract: A method for assisting in locating a position of a mobile wireless device includes: obtaining location information of an approximate location of the mobile wireless device; generating an almanac of base stations based at least in part on proximity of locations of the base stations to the approximate location of the mobile wireless device, the almanac of base stations comprising at least one cooperative terrestrial base station that can communicate with the mobile wireless device in at least one mode and at least one uncooperative terrestrial base station capable of bi-directional communications and configured to prevent data and voice communications with the mobile wireless device, the at least one uncooperative terrestrial base station being configured to acknowledge a message received from the mobile wireless device; and providing the almanac of base stations to the mobile wireless device.

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Abstract: Methods and apparatuses for position determination and other operations. In one embodiment of the present invention, a mobile station uses wireless signals from a plurality of wireless networks (e.g., with different air interfaces and/or operated by different service providers) for position determination (e.g., for data communication, for obtaining time and/or frequency information, for range measurement, for sector or altitude estimation). In one embodiment of the present invention, mobile stations are used to harvest statistical data about wireless access points (e.g., the locations of mobile stations that have received signals from the wireless access points, such as from cellular base stations, wireless local area network access points, repeaters for positioning signals, or other wireless communication transmitters) and to derive location information (e.g., position and coverage area of the wireless access points) for the wireless networks from the collected statistical data.

Abstract: A mobile wireless device locating method at a mobile wireless device includes: determining, based at least in part on measurements of first signals, first location information for the mobile wireless device; sending a request for transceiver information based on the first location information; receiving the transceiver information at the mobile wireless device, the transceiver information including transceiver identifiers and corresponding locations; measuring second signals from at least some of the transceivers included in the transceiver information, at least one of the second signals being from an uncooperative terrestrial base station capable of bi-directional communications and configured to prevent data and/or voice communications with the mobile wireless device; and determining second location information for the mobile wireless device using information obtained from measuring the second signals.

Abstract: A method for assisting in locating a position of a mobile wireless device includes: obtaining location information of an approximate location of the mobile wireless device; generating an almanac of base stations based at least in part on proximity of locations of the base stations to the approximate location of the mobile wireless device, the almanac of base stations comprising at least one cooperative terrestrial base station that can communicate with the mobile wireless device in at least one mode and at least one uncooperative terrestrial base station capable of bi-directional communications and configured to prevent data and voice communications with the mobile wireless device, the at least one uncooperative terrestrial base station being configured to acknowledge a message received from the mobile wireless device; and providing the almanac of base stations to the mobile wireless device.

Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

Abstract: A method and system for assisting mobile stations to locate a satellite use an efficient messaging format. A server computes a correction between coarse orbit data of a satellite and precise orbit data of the satellite. A coordinate system is chosen such that variation of the correction is substantially smooth over time. The server further approximates the correction with mathematical functions to reduce the number of bits necessary for transmission to a mobile station. The mobile station, upon receiving the coefficients, evaluates the mathematical functions using the coefficients and a time of applicability (e.g., the current time), converts the evaluated result to a standard coordinate system, and applies the conversion result to the coarse orbit data to obtain the precise orbit data.

Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract: Disclosed are systems, methods and techniques for calibrating an altimeter of a mobile device. For example, a characterized motion of a mobile device may be used to infer an altitude of the mobile device. If it is further inferred that the mobile device is in an outdoor environment, an altitude of the mobile device may be based on application of an estimated location of the mobile device to an altitude terrain map.